A mesoporous silica nanoparticulate/β-TCP/BG composite drug delivery system for osteoarticular tuberculosis therapy

Tomioka, 2006, Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities, Curr Pharm Design, 12, 4047, 10.2174/138161206778743646 Vashishtha, 2009, WHO global tuberculosis control report 2009: tuberculosis elimination is a distant dream, Indian Pediatr, 46, 401 Global tuberculosis control: surveillance, planning, financing. WHO report 2008, available at: http://www.who.int/tb/publications/global_report/2008/pdf/fullreport.pdf. Raviglione, 2001 Huebner, 1995, The changing face of tuberculosis, Annu Rev Med, 46, 47, 10.1146/annurev.med.46.1.47 Tuli, 1997 Malaviya, 2003, Arthritis associated with tuberculosis, Best Pract Res Cl Rh, 17, 319, 10.1016/S1521-6942(02)00126-2 Mahowald, 2000 Meier, 1995, Mycobacterial and fungal infections of bone and joints, Curr Opin Rheumatol, 7, 329, 10.1097/00002281-199507000-00011 Puttick, 1995, Soft tissue tuberculosis: a series of 11 cases, J Rheumatol, 22, 1321 Dutt, 1989, The treatment of extrapulmonary tuberculosis, Semin Resp Infect, 4, 225 Garrido, 1988, A review of peripheral tuberculous arthritis, Semin Arthritis Rheu, 18, 142, 10.1016/0049-0172(88)90007-8 Sequeira, 2000, Joint and bone tuberculosis: current diagnosis and treatment, Am J Therap, 7, 393, 10.1097/00045391-200007060-00009 Bass, 1994, Treatment of tuberculosis and tuberculosis infection in adults and children, Am J Respir Crit Care Med, 149, 1359, 10.1164/ajrccm.149.5.8173779 Davidson, 1992, Drug treatment of tuberculosis – 1992, Drugs, 43, 651, 10.2165/00003495-199243050-00003 Kameda, 1980, A case of acute hepatitis curred during treatment with isoniazid and rifampicin, Kekkaku, 55, 247 Schaberg, 1995, The dark side of antituberculosis therapy: adverse events involving liver function, Eur Respir J, 8, 1247, 10.1183/09031936.95.08081247 Agal, 2005, Monitoring and management of antituberculosis drug induced hepatotoxicity, J Gastroen Hepatol, 20, 1745, 10.1111/j.1440-1746.2005.04048.x Yew, 2006, Antituberculosis drugs and hepatotoxicity, Respirology, 11, 699, 10.1111/j.1440-1843.2006.00941.x Tuli, 2002, General principles of joint and bone tuberculosis, Clin Orthop Relat R, 398, 11, 10.1097/00003086-200205000-00003 Luk, 2000, Spinal tuberculosis, Curr Opin Orthop, 11, 196, 10.1097/00001433-200006000-00007 Kailasam, 1994, Bioavailability and chemotherapeutic activity of clofazimine against Mycobacterium avium complex infections in beige mice following a single implant of a biodegradable polymer, J Antimicrob Chemoth, 33, 273, 10.1093/jac/33.2.273 Manisha, 2001, Sustained release of isoniazid from a single injectable dose of poly (dl-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis, Int J Antimicrob Ag, 17, 115, 10.1016/S0924-8579(00)00330-7 Vallet-Regí, 2007, Mesoporous materials for drug delivery, Angew Chem Int Ed, 46, 7548, 10.1002/anie.200604488 Shi, 2009, Enhancing alendronate release from a novel PLGA/hydroxyapatite microspheric system for bone repairing applications, Pharm Res, 26, 422, 10.1007/s11095-008-9759-0 Tourné-Péteilh, 2003, The potential of ordered mesoporous silica for the storage of drugs: the example of a pentapeptide encapsulated in an MSU-Tween 80, Chem Phys Chem, 4, 281, 10.1002/cphc.200390045 Porter, 2008, Lipid-based systems for the enhanced delivery of poorly water-soluble drugs, Adv Drug Deliver Rev, 60, 615, 10.1016/j.addr.2007.10.009 Sill, 2008, Electrospinning: applications in drug delivery and tissue engineering, Biomaterials, 29, 1989, 10.1016/j.biomaterials.2008.01.011 Hilder, 2008, Carbon nanotubes as drug delivery nanocapsules, Curr Appl Phys, 8, 258, 10.1016/j.cap.2007.10.011 Zhang, 2008, An ionically crosslinked hydrogel containing vancomycin coating on a porous scaffold for drug delivery and cell culture, Int J Pharm, 353, 74, 10.1016/j.ijpharm.2007.11.023 Pandey, 2003, Poly(dl-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis, J Antimicrob Chemoth, 52, 981, 10.1093/jac/dkg477 Dutt, 2001, Liposomes and PLG microparticles as sustained release antitubercular drug carriers-an in vitro and in vivo study, Int J Antimicrob, 18, 245, 10.1016/S0924-8579(01)00373-9 Dutt, 2001, Sustained release of isoniazid from a single injectable dose of poly (dl-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis, Int J Antimicrob, 17, 115, 10.1016/S0924-8579(00)00330-7 Shi, 2009, Novel mesoporous silica-based antibiotic releasing scaffold for bone repair, Acta Biomater, 5, 1697, 10.1016/j.actbio.2009.01.010 Vallet-Regí, 2001, A new property of MCM-41: drug delivery system, Chem Mater, 13, 308, 10.1021/cm0011559 Doadrio, 2004, Mesoporous SBA-15 HPLC evaluation for controlled gentamicin drug delivery, J Control Release, 97, 125, 10.1016/j.jconrel.2004.03.005 Initial therapy for tuberculosis in the era of multi-drug resistance: recommendation of the advisory committee for the elimination of tuberculosis. Recommendations and Reports 1993, available at: http://www.cdc.gov/mmwr/PDF/rr/rr4207.pdf. Clark, 2010 Gürsoy, 2004, Co-encapsulation of isoniazid and rifampicin in liposomes and characterization of liposomes by derivative spectroscopy, Inter J Pharm, 271, 115, 10.1016/j.ijpharm.2003.10.033 Shrutidevi, 2004, Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose level, Inter J Pharm, 276, 41, 10.1016/j.ijpharm.2004.02.019 Guo, 2004, Repair of large articular cartilage defects with implants of autologous mesenchymal stem cells seeded into beta-tricalcium phosphate in a sheep model, Tissue Eng, 10, 1818, 10.1089/ten.2004.10.1818 Guo, 2004, Repair of osteochondral defects with autologous chondrocytes seeded onto bioceramic scaffold in sheep, Tissue Eng, 10, 1830, 10.1089/ten.2004.10.1830 Radu, 2004, A polyamidoamine dendrimer-capped mesoporous silica nanosphere-based gene transfection reagent, J Am Chem Soc, 126, 13216, 10.1021/ja046275m Wei, 2009, Preparation and characterization of bioactive mesoporous wollastonite–Polycaprolactone composite scaffold, Biomaterials, 30, 1080, 10.1016/j.biomaterials.2008.10.046 Li, 2008, A mesoporous bioactive glass/polycaprolactone composite scaffold and its bioactivity behavior, J Biomed Mater Res A, 84, 84 Mortera, 2008, Synthesis and characterization of MCM-41 spheres inside bioactive glass–ceramic scaffold, Chem Eng J, 137, 54, 10.1016/j.cej.2007.07.094 Cauda, 2008, SBA-15 ordered mesoporous silica inside a bioactive glass-ceramic scaffold for local drug delivery, J Mater Sci Mater Med, 19, 3303, 10.1007/s10856-008-3468-4 Zhang, 1994, A mechanistic study of antibiotic release from biodegradable poly (d,l-lactide) cylinders, J Control Release, 31, 129, 10.1016/0168-3659(94)00011-5 Bemer-Melchior, 2000, Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex, J Antimicrob Chemother, 46, 571, 10.1093/jac/46.4.571 Rastogi, 1996, In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages, Curr Microbiol, 33, 167, 10.1007/s002849900095